Aman Mehta

阿曼·米塔

, third generation of

第三代

Torrent Group

种子组

's founder Mehta family, was on Tuesday appointed Managing Director of the conglomerate's flagship

创始人梅塔家族于周二被任命为该企业集团旗舰公司的董事总经理

Torrent Pharmaceuticals

Torrent制药公司

. He is son of

. 他是

Samir Mehta

萨米尔·梅塔

, the current chairman of Torrent Pharma. Aman was appointed as a whole-time director on the board of

，Torrent制药公司现任董事长。阿曼被任命为董事会的全职董事。

Torrent Pharma

Torrent制药

in August 2022, marking the beginning of the third-generation leadership taking charge at the company.

2022年8月，标志着第三代领导层开始掌管公司。

'We are pleased to share that as part of our long-term strategic vision and succession planning, the Board has approved the appointment of Aman Mehta as Managing Director, effective August 1, 2025,'

“我们很高兴地分享，作为我们长期战略愿景和继任计划的一部分，董事会已批准任命阿曼·梅塔为董事总经理，自2025年8月1日起生效。”

Torrent Pharma

Torrent制药公司

said in a statement.

声明中说道。

This appointment, it said, is aligned with the firm's commitment to building a strong, future-ready leadership team capable of delivering sustainable value to all stakeholders.

该任命符合该公司打造强大、为未来做好准备的领导团队的承诺，该团队能够为所有利益相关者提供可持续的价值。

The company was founded in 1959 by Aman's grandfather, Uttambhai Nathalal Mehta, who was a medical representative with Sandoz. The group was later led by his sons, Samir and Sudhir Mehta. Samir Mehta currently serves as the Chairman of Torrent Pharma, while Sudhir is the Chairman Emeritus.

该公司由阿曼的祖父乌坦拜·纳萨尔·梅塔于1959年创立，他曾在山德士担任医药代表。该集团后来由他的儿子萨米尔和苏迪尔·梅塔领导。萨米尔·梅塔目前担任Torrent制药公司的董事长，而苏迪尔是名誉董事长。

Aman, 33, holds a Bachelor's of Economics from the Boston University and an MBA from Columbia University, New York. He joined the Torrent Group in 2013.

阿曼，33岁，拥有波士顿大学经济学学士学位和纽约哥伦比亚大学工商管理硕士学位。他于2013年加入Torrent集团。

Live Events

现场活动

'He has been Director at Torrent Pharma since August 2022 and heads the India and RoW

他自2022年8月起担任Torrent Pharma的总监，并负责印度和RoW地区。

Business

商业

. His key achievement has been the successful integration of the

。他的主要成就是成功地整合了

Unichem acquisition

尤尼化学收购

, which has created significant value for the company,' his profile on the company website says.

，这为公司创造了巨大的价值，”公司网站上的个人简介写道。

During his journey with the Group, he has held leadership roles across both power and pharma verticals.

在该集团工作期间，他曾担任电力和制药两个垂直领域的领导职务。

Starting with pharmaceuticals, Torrent made a foray into the power sector in 1996 and in gas business in 2018. When founder U N Mehta passed away in 1998, Sudhir, his eldest son, took charge as chairman of Torrent Pharma and Torrent Power. The group has since diversified into adjacencies - hospitals and diagnostics in healthcare and renewables, thermal, pumped hydro storage (PHS) and green hydrogen in energy.

从制药业开始，Torrent于1996年进军电力行业，并于2018年涉足天然气业务。1998年创始人U N Mehta去世后，其长子Sudhir接任Torrent Pharma和Torrent Power的董事长。此后，该集团逐步向相关领域多元化发展——在医疗保健领域扩展至医院和诊断业务，在能源领域扩展至可再生能源、热能、抽水蓄能（PHS）和绿色氢能。

.

。

In 2014, Sudhir, now 71, gave up his position as chairman of Torrent Pharma. Samir, now 62, took over as the new chairman. Four years later, Sudhir relinquished chairmanship of Torrent Power and retired from active business life. Samir took over as executive chairman of the group.

2014 年，现年 71 岁的苏迪尔辞去了 Torrent Pharma 董事长的职务。现年 62 岁的萨米尔接任新董事长。四年后，苏迪尔放弃了 Torrent Power 的董事长职位，并退出了积极的商业生活。萨米尔接任集团执行董事长。

Sudhir and Samir have two sons each. All four have joined the group in various capacities.

苏迪尔和萨米尔各有两个儿子。这四个儿子都以不同的身份加入了该集团。

Jinal, 42, Sudhir's eldest son, is vice chairman and managing director of Torrent Power and head of Torrent Gas. His younger brother Varun, 36, is director in Torrent Power and in-charge of new business verticals.

42 岁的吉纳尔是苏迪尔的长子，担任 Torrent Power 的副董事长兼董事总经理以及 Torrent Gas 的负责人。36 岁的弟弟瓦伦担任 Torrent Power 的董事，负责新业务板块。

Shaan, 27, younger son of Samir, is head of strategic planning at Torrent Pharma.

沙恩，27岁，萨米尔的小儿子，是Torrent制药公司战略规划部门的负责人。

In his role as Executive Director at Torrent Pharma, Aman was primarily involved in the India business, Torrent's largest revenue contributor, according to his profile provided by the company.

根据公司提供的个人简介，Aman 在 Torrent Pharma 担任执行董事期间，主要负责 Torrent 最大的收入来源——印度业务。

He played an instrumental role in the integration of the

他在整合过程中发挥了关键作用

Unichem

尤尼化学

acquisition and the strategic identification and integration of Curatio Healthcare, both of which delivered substantial value and synergies to the company.

收购以及对Curatio Healthcare的战略识别和整合，这两项都为公司带来了巨大的价值和协同效应。

Since his appointment as Whole time Director, he has continued to make a significant impact on the India business growth and transformation journey. Notable contribution of his leadership includes market share expansion through organic growth and strategic in-licensing, turnaround in cardiac and diabetes portfolio with significant improvement in performance and ranking and launch of consumer health division.

自他被任命为全职董事以来，他继续对印度业务的增长和转型历程产生重大影响。其领导的显著贡献包括通过有机增长和战略性授权扩大市场份额，通过显著提升业绩和排名扭转心脏科和糖尿病产品组合的局面，以及推出消费者健康部门。

.

。

Under his leadership, R&D has been more sharply aligned with business strategy, with a focus on differentiated product development and faster execution of critical projects. His inputs have helped drive operational excellence initiatives across manufacturing and supply chain functions, leading to increased focus on productivity, cost efficiency, margins, and service levels..

在他的领导下，研发与业务战略的结合更加紧密，重点放在差异化产品开发和加快关键项目的执行速度上。他的贡献帮助推动了制造和供应链职能的运营卓越计划，使得生产力、成本效率、利润率和服务水平得到了更多的关注。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)